𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer

✍ Scribed by Takehiko Segawa; Toshiyuki Kamoto; Hidefumi Kinoshita; Yasuharu Kunishima; Koji Yoshimura; Akihiro Ito; Takeshi Takahashi; Shin Higashi; Eijiro Nakamura; Hirofumi Nishiyama; Noriyuki Ito; Shingo Yamamoto; Tomonori Habuchi; Osamu Ogawa

Publisher
Springer
Year
2005
Tongue
English
Weight
378 KB
Volume
10
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Clinical experience with intravenous est
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma
✍ David B. Solit; Michael Morris; Susan Slovin; Tracy Curley; Lawrence Schwartz; S πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 87 KB

## Abstract ## BACKGROUND The combination of paclitaxel, oral estramustine phosphate (EMP), and carboplatin (TEC) has shown antitumor activity in patients with castrate, metastatic prostate carcinoma. To improve the therapeutic efficacy and reduce the toxicity of TEC, the authors substituted intra

Phase II trial of paclitaxel, estramusti
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
✍ David C. Smith; Christopher H. Chay; Rodney L. Dunn; Jude Fardig; Peg Esper; Kar πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 127 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone‐refractory prostate carcinoma. The authors conducted this clinical trial t

Oral estramustine and cyclophosphamide i
Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study
✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 2 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi